CN107735081A - 用于治疗抑郁症的方法和药盒 - Google Patents

用于治疗抑郁症的方法和药盒 Download PDF

Info

Publication number
CN107735081A
CN107735081A CN201680029082.XA CN201680029082A CN107735081A CN 107735081 A CN107735081 A CN 107735081A CN 201680029082 A CN201680029082 A CN 201680029082A CN 107735081 A CN107735081 A CN 107735081A
Authority
CN
China
Prior art keywords
patient
esketamine
chinese mugwort
during
induction period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680029082.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.辛格
I.卡尔斯
E.达伊
W.C.德雷维特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN107735081A publication Critical patent/CN107735081A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
CN201680029082.XA 2015-05-20 2016-05-20 用于治疗抑郁症的方法和药盒 Pending CN107735081A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
US62/164026 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (1)

Publication Number Publication Date
CN107735081A true CN107735081A (zh) 2018-02-23

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029082.XA Pending CN107735081A (zh) 2015-05-20 2016-05-20 用于治疗抑郁症的方法和药盒

Country Status (20)

Country Link
US (1) US20160338977A1 (https=)
EP (1) EP3297618A4 (https=)
JP (1) JP2018515557A (https=)
KR (1) KR20180008634A (https=)
CN (1) CN107735081A (https=)
AU (3) AU2016263598A1 (https=)
CA (1) CA2986477A1 (https=)
CL (1) CL2017002904A1 (https=)
CO (1) CO2017011564A2 (https=)
DO (1) DOP2017000268A (https=)
EA (1) EA201792545A1 (https=)
EC (1) ECSP17077930A (https=)
GT (1) GT201700246A (https=)
HK (1) HK1252937A1 (https=)
IL (1) IL255463A (https=)
MA (1) MA42135A (https=)
MX (1) MX2017014797A (https=)
PE (1) PE20180260A1 (https=)
PH (1) PH12017502103A1 (https=)
WO (1) WO2016187491A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112188889A (zh) * 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
CN112702995A (zh) * 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
CN113038941A (zh) * 2018-09-28 2021-06-25 赛隆制药股份公司 用于通过肺部施用治疗抑郁症的方法中的氯胺酮组合物
CN114126595A (zh) * 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US20220304950A1 (en) * 2019-08-28 2022-09-29 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021242504A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceuticals, Inc. Methods for treating depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
CN104519878A (zh) * 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
WO2016044150A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
EP2830604A4 (en) * 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
CN104519878A (zh) * 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
WO2016044150A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112188889A (zh) * 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN113038941A (zh) * 2018-09-28 2021-06-25 赛隆制药股份公司 用于通过肺部施用治疗抑郁症的方法中的氯胺酮组合物
CN112702995A (zh) * 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12016832B2 (en) 2018-10-05 2024-06-25 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN114126595A (zh) * 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
EP3297618A1 (en) 2018-03-28
PE20180260A1 (es) 2018-02-05
JP2018515557A (ja) 2018-06-14
IL255463A (en) 2018-01-31
PH12017502103A1 (en) 2018-05-07
AU2016263598A1 (en) 2017-11-23
HK1252937A1 (zh) 2019-06-06
CL2017002904A1 (es) 2018-04-20
MX2017014797A (es) 2018-02-15
EP3297618A4 (en) 2019-01-23
AU2021215155A1 (en) 2021-09-02
MA42135A (fr) 2018-03-28
GT201700246A (es) 2019-07-29
WO2016187491A1 (en) 2016-11-24
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
CA2986477A1 (en) 2016-11-24
EA201792545A1 (ru) 2018-05-31
KR20180008634A (ko) 2018-01-24
ECSP17077930A (es) 2018-02-28

Similar Documents

Publication Publication Date Title
CN107735081A (zh) 用于治疗抑郁症的方法和药盒
US20250255835A1 (en) Methods For The Treatment Of Depression
Bahr et al. Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant
Detke et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Lum et al. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
Vijiaratnam et al. Therapeutic strategies to treat or prevent off episodes in adults with Parkinson’s disease
CA3086478A1 (en) Esketamine for the treatment of depression
Ekambaram et al. Medications used for pediatric insomnia
MX2014010939A (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
US20240325296A1 (en) Esketamine for the treatment of depression
JP7273037B2 (ja) ３－メチルメトカチノンの使用
US20200009081A1 (en) Delivery Of Esketamine For The Treatment Of Depression
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
CA3153856A1 (en) Intranasal administration of esketamine
US20140309271A1 (en) Treatment of autistic spectrum disorder
Kobayashi et al. Ketamine for acute catatonia: A case report
US20190328686A1 (en) Treatment of moderate and severe gastroparesis
TW200821296A (en) Use of sertindole for the preventive treatment of suicidal behaviour
Khouzam Treatment Resistant Depression: Review of its Therapeutic Interventions
Pops Pkt: sodium 12 mEq+ potassium 5 mEq+ chloride 10 mEq+ citrate 7 mEq+ dextrose 5 gm+ calories 22 per 6.2 gm
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
Rizek et al. Management of Advanced Parkinson’s Disease
MX2014002965A (es) Combinaciones que comprenden un modulador del receptor de s1p.
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180223